Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
By M. Silverberg, J. Satsangi, T. Ahmad, I. Arnott, C. Bernstein, S. Brant, R. Caprilli, J. Colombel, C. Gasche, K. Geboes and 12 more. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2005
3,349 citations recorded by the source corpus.
The discovery of a series of genetic and serological markers associated with disease susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an integrated classification system involving clinical, serological and genetic parameters. The Working Party has reviewed current clinical classification systems in Crohn's disease, ulcerative colitis and indeterminate colitis, and provided recommendations for clinical classification in practice. Progress with respect to integrating serological and genetic markers has been examined in detail, and the implications are discussed. While an integrated system is not proposed for clinical use at present, the introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Subfields: Epidemiology, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/e8d197a8bc142117006fcc060eed75af52998dec
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Genetics
- W. Sandborn
- J. Colombel
- L. Peyrin-Biroulet
- Ashwin N. Ananthakrishnan
- E. Loftus
- Markus F. Neurath
- Daniel C. Baumgart
Citations in the corpus
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. (2012, neutral): “167 The co-primary endpoints were proportion of patients with (1) clinical remission at week 8; (2) clinical remission at week 52.”
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) (2009, methodology): “The extent of colitis in our study was based on endoscopic findings, which should be an advantage compared to the combination of sigmoidoscopy and barium enema used by others [27].”
- Impact of Omega-3 Fatty Acids on the Gut Microbiota (2017, background): “In IBD, the prolonged activation of NF-κB leads to the production of pro-inflammatory cytokines [80].”
- Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) (2010, background): “The definitions for extent of disease have been elucidated in the Montreal disease classification.(58) Disease extent may change over time in any individual with ulcerative colitis.”
- ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents (2013, positive): “A major reference point was the Paris classification (8), an expert-consensus document providing a pediatric-specific modification of the Montreal classification of IBD (9), which specifically has highlighted those phenotypic characteristics that are either more common in or unique to pediatric-onse”